BNC-210

BNC-210
Clinical data
ATC code	none;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name L-Isoleucyl-L-tryptophan;
PubChem CID	7019084;
ChemSpider	5382052;
CompTox Dashboard (EPA)	DTXSID101029559 ;
Chemical and physical data
Formula	C17H23N3O3
Molar mass	317.389 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N;
	InChI InChI=1S/C17H23N3O3/c1-3-10(2)15(18)16(21)20-14(17(22)23)8-11-9-19-13-7-5-4-6-12(11)13/h4-7,9-10,14-15,19H,3,8,18H2,1-2H3,(H,20,21)(H,22,23)/t10-,14-,15-/m0/s1; Key:BVRPESWOSNFUCJ-LKTVYLICSA-N;

BNC210 (also known as IW-4123 during its time licensed to Ironwood Pharmaceuticals) is an anxiolytic drug that acts via negative allosteric modulation of the α₇-nicotinic acetylcholine receptor,^[1] by Bionomics Limited. It demonstrates clinically significant anxiety reduction in both animal models and in Phase I trials.^[2]

It appears to be devoid of significant sedation or memory-impairing side effects, as well as lacking addictive potential in rat discriminatory models.^[3]

Phase I trials have shown no serious side effects.

Bionomics previously licensed it to Ironwood Pharmaceuticals in January 2012, where it was known as IW-2143. In December 2012, IW-2143 begun undergoing phase I clinical trials in the United States,^[4] but in November 2014, was released back to Bionomics in a mutual agreement.^[5] Bionomics will now continue development and clinical testing, with Ironwood receiving a royalty for their work done.

As of April 2015, BNC210 is in phase II clinical trials.^[6]

References

^ http://www.bionomics.com.au/upload/investors/asx-announcements/4736/ASX695%20%20BNC210%20Phase%201b%20initiation.pdf
^ "Bionomics - Pipeline". Retrieved 2010-11-09. Bionomics has discovered a novel compound, BNC210, that offers dramatic competitive advantages over existing treatments
^ O'Connor, S.; Andriambeloson, E.; Huyard, B.; Wagner, S.; Sleebs, B.; Quasi, N.; Bui, C.; Street, I. "BNC210: A Novel Compound with Potent Anxiolytic Activity" (PDF). Bionomics Limited. Retrieved 2010-11-09. By applying a targeted medicinal chemistry strategy beginning from a compound cited in the literature, Bionomics has developed BNC210
^ http://investor.ironwoodpharma.com/releasedetail.cfm?ReleaseID=733540
^ http://www.biotechdaily.com.au/media/backissues/2014/11%20Nov/BD%20Biotech%20Daily%20Nov%2011.pdf
^ Bionomics Limited. "www.prnewswire.com" (HTML). PRNewswire. Retrieved 2015-06-10.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[1] ttp://www.bionomics.com.au/upload/investors/asx-announcements/4736/ASX695%20%20BNC210%20Phase%201b%20initiation.pdf

[2] "Bionomics - Pipeline". Retrieved 2010-11-09. Bionomics has discovered a novel compound, BNC210, that offers dramatic competitive advantages over existing treatments

[3] O'Connor, S.; Andriambeloson, E.; Huyard, B.; Wagner, S.; Sleebs, B.; Quasi, N.; Bui, C.; Street, I. "BNC210: A Novel Compound with Potent Anxiolytic Activity" (PDF). Bionomics Limited. Retrieved 2010-11-09. By applying a targeted medicinal chemistry strategy beginning from a compound cited in the literature, Bionomics has developed BNC210

[4] ttp://investor.ironwoodpharma.com/releasedetail.cfm?ReleaseID=733540

[5] ttp://www.biotechdaily.com.au/media/backissues/2014/11%20Nov/BD%20Biotech%20Daily%20Nov%2011.pdf

[BionomicsLimited-6] Bionomics Limited. "www.prnewswire.com" (HTML). PRNewswire. Retrieved 2015-06-10.

[1]

[2]

[3]

[4]

[5]

[6]

v t e Anxiolytics (N05B)
5-HT_1ARTooltip 5-HT1A receptor agonists	Buspirone Gepirone Tandospirone
GABA_ARTooltip GABAA receptor PAMsTooltip positive allosteric modulators	Benzodiazepines: Adinazolam Alprazolam Bromazepam Camazepam Chlordiazepoxide Clobazam Clonazepam Clorazepate Clotiazepam Cloxazolam Diazepam^# Ethyl loflazepate Etizolam Fludiazepam Halazepam Ketazolam Lorazepam^# Medazepam Nordazepam Oxazepam Pinazepam Prazepam; Others: Alpidem^‡ Barbiturates (e.g., phenobarbital) Carbamates (e.g., meprobamate) Carisoprodol Chlormezanone^‡ Ethanol (alcohol) Etifoxine
Hypnotics	Zopiclone
Gabapentinoids (α₂δ VDCC blockers)	Gabapentin Gabapentin enacarbil Phenibut Pregabalin
Antidepressants	SSRIsTooltip Selective serotonin reuptake inhibitors (e.g., escitalopram) SNRIsTooltip Serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine) SARIsTooltip Serotonin antagonist and reuptake inhibitors (e.g., trazodone) TCAsTooltip Tricyclic antidepressants (e.g., clomipramine^#) TeCAsTooltip Tetracyclic antidepressants (e.g., mirtazapine) MAOIsTooltip Monoamine oxidase inhibitors (e.g., phenelzine); Others: Agomelatine Bupropion Tianeptine Vilazodone Vortioxetine
Antipsychotics	Quetiapine Flupentixol
Sympatholytics (Antiadrenergics)	Alpha-1 blockers (e.g., prazosin) Alpha-2 agonists (e.g., clonidine, dexmedetomidine, guanfacine) Beta blockers (e.g., propranolol)
Others	Benzoctamine Cycloserine Fabomotizole Hydroxyzine Lorpiprazole Mebicar Mepiprazole Nicotine Opipramol Oxaflozane^‡ Phenaglycodol Phenibut Picamilon Selank Tiagabine Tofisopam Validolum
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

See also

References